Navigation Links
Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe
Date:7/28/2010

NATICK, Massachusetts, July 28, 2010 /PRNewswire-FirstCall/ --

- Company Expands Market-leading Family of Neurovascular Stents

Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launches of the Neuroform EZ(TM) Stent System, its fourth-generation intracranial aneurysm stent system designed for use in conjunction with endovascular coiling to treat wide-necked aneurysms. The Company plans to launch the product immediately in both markets.

The Neuroform EZ Stent System is engineered to provide flexibility and conformability, especially in tortuous brain anatomy. It employs Boston Scientific's proprietary Segmental(TM) Expansion technology, designed to enhance stent anchoring and stability. The product features the proven hybrid cell design of prior-generation Neuroform Stents while incorporating a simplified, single-operator delivery system intended to facilitate preparation, delivery and positioning of the stent.

The first Neuroform EZ Stent was implanted in the U.S. by Demetrius Lopes, M.D., of the Rush University Medical Center in Chicago, and the first European procedure was performed by Professor Laurent Spelle, M.D., Ph.D., at Foundation Rothschild Hospital, Beaujon School of Medicine in Paris.

"The Neuroform EZ Stent System performed well in a very challenging first procedure," said Dr. Lopes. "The smooth transfer of the stent into the catheter, combined with excellent support, stability and visibility, facilitated accurate stent placement."

"The improved delivery system of the Neuroform EZ Stent helped me to place the stent exactly where I planned," said Professor Spelle. "In my experience, Boston Scientific's new system is easier to use compared to its previous microdelivery system and should offer benefits for both physicians and patients."

"Boston Scientific is pleased to offer this new technology, which is designed to help physicians simplify these complex neurovascular procedures," said Mark Paul, President of Boston Scientific's Neurovascular Division. "The Neuroform EZ Stent System reinforces our commitment to providing advanced treatment options focused on improving patient care."

Boston Scientific will demonstrate its Neuroform EZ Stent System at the 7th Annual Society of NeuroInterventional Surgery (SNIS) Meeting, July 26 - 30 in Carlsbad, California.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, clinical outcomes and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:
    Paul Donovan
    +1-508-650-8541 (office)
    +1-508-667-5165 (mobile)
    Media Relations
    Boston Scientific Corporation

    Larry Neumann
    +1-508-650-8696 (office)
    Investor Relations
    Boston Scientific Corporation



'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
2. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
3. Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System
4. Boston Scientific Announces Settlement of DOJ Investigation Relating to Post-Market Surveys Conducted By Guidant
5. Boston Scientific Announces Election of Nelda Connors to Its Board of Directors
6. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. Boston Scientific to Participate in Piper Jaffray Health Care Conference
9. Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent
10. Boston Scientific Announces Sponsorship of World Diabetes Day Campaign 2009
11. Boston Scientifics Urology/Gynecology Products Featured in Studies at Global Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):